CTLA4 and neoplasm: Nevertheless, only 10% to 30% of patients benefit from this immune checkpoint blocking, possibly due to the insufficient activation or inactivation of tumor-reactive CTLs or the inability to infiltrate the tumor, while anti-CTLA-4 in conjunction with anti-PD-1 antibodies can lead to severe immune-related toxicity in tumors treatment [157].